Nivolumab in patients with relapsed or refractory hematologic malignancy: Preliminary results of a phase ib study Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Chromosome Aberrations
  • Chromosomes, Human, Pair 9
  • Lymphoma, B-Cell
  • Lymphoma, T-Cell
  • Multiple Myeloma

abstract

  • Nivolumab was well tolerated and exhibited antitumor activity in extensively pretreated patients with relapsed or refractory B- and T-cell lymphomas. Additional studies of nivolumab in these diseases are ongoing.

publication date

  • August 10, 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5019749

Digital Object Identifier (DOI)

  • 10.1200/JCO.2015.65.9789

PubMed ID

  • 27269947

Additional Document Info

start page

  • 2698

end page

  • 704

volume

  • 34

number

  • 23